Nutritional considerations for off-label use remain unclear and, given the rapidly growing public use of GLP-1s, are an important area of needed research
The immediate priority is to address the drug delivery challenge
It acts on the brain to increase feelings of fullness, slows stomach emptying to help you stay satisfied after meals, and signals the pancreas to release insulin when blood sugar levels rise
It plays a critical role in metabolic health by signaling your brain that you are full and telling your pancreas to release insulin
Oral formulations will grow to capture 25% share as bioavailability improves and new small-molecule GLP-1s reach the market, appealing to segments seeking greater convenience or avoiding injection-site issues
Microdosing, by contrast, involves maintaining doses below these established starting points or progressing more slowly than recommended